Evidence map›Paper›PMID 30410363›Full record

ArticleOncoTargets and therapy2018

Platelet-to-lymphocyte ratio and lymphocyte-to-white blood cell ratio predict the efficacy of neoadjuvant chemotherapy and the prognosis of locally advanced gastric cancer patients treated with the oxaliplatin and capecitabine regimen.

Cheng Tang, Xi Cheng, Shan Yu, Yan Wang, Jun Hou, Qian Li, Zhenbin Shen, Tianshu Liu, Yuehong Cui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 5 pooled it
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Cheng TangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; cui.yuehong@zs-hospital.sh.cn; liutianshu1969@126.com.
Xi ChengDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; cui.yuehong@zs-hospital.sh.cn; liutianshu1969@126.com.
Shan YuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; cui.yuehong@zs-hospital.sh.cn; liutianshu1969@126.com.
Yan WangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; cui.yuehong@zs-hospital.sh.cn; liutianshu1969@126.com.
Jun HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Qian LiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; cui.yuehong@zs-hospital.sh.cn; liutianshu1969@126.com.
Zhenbin ShenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; cui.yuehong@zs-hospital.sh.cn; liutianshu1969@126.com.
Yuehong CuiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; cui.yuehong@zs-hospital.sh.cn; liutianshu1969@126.com.
Sun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany studies have discussed the relationship between routine blood parameters and the prognosis of gastric cancer patients; however, few studies focused on the association of routine blood parameters with the efficacy of neoadjuvant chemotherapy (NAC). PATIENTS AND

methodsWe retrospectively collected routine blood parameters and other clinicopathological data of 104 patients with locally advanced gastric cancer (LAGC) who received the oxaliplatin and capecitabine regimen as NAC from June 2010 to March 2016. The objective response rate (ORR), pathological remission rate (pRR), overall survival (OS), and time to recurrence (TTR) were analyzed through different statistical methods, such as Chi-squared test, log-rank test, logistic regression, and Cox regression.

resultsIn the multivariate analysis, a high platelet-to-lymphocyte ratio (PLR) (≥130.7) predicted a low ORR (OR =5.927, 95% CI: 2.184-16.089) and a low pRR (OR =8.343, 95% CI: 2.178-31.962), while a high lymphocyte-to-white blood cell ratio (LWR) (≥0.228) independently predicted a high ORR (OR =0.118, 95% CI: 0.031-0.448) and a high pRR (OR =0.096, 95% CI: 0.021-0.426). High lymphocyte level (≥1.750×10

conclusionIn patients with LAGC treated with the oxaliplatin and capecitabine regimen as NAC, a low PLR (<130.7) and a high LWR (≥0.228) independently predicted a high ORR and pRR. High monocyte level (≥0.215×10

Indexed as

chemotherapygastric cancerLWRPLR

Identifiers

PMID30410363
PMCPMC6200072
OpenAlexW2896539967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.